CoChat

Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes

Leibowitz, Mark D., Ardecky, Robert J., Boehm, Marcus F., Broderick, Carol L., Carfagna, Mark A., Crombie, Diane L., D’Arrigo, Jennifer, Etgen, Garrett J., Faul, Margaret M., Grese, Timothy A., Havel, Henry, Hein, Nancy I., Heyman, Richard A., Jolley, Diane, Klausing, Kay, Liu, Sha, Mais, Dale E., Mapes, Christopher M., Marschke, Keith B., Michellys, Pierre-Yves, Montrose-Rafizadeh, Chahrzad, Ogilvie, Kathleen M., Pascual, Bernadette, Rungta, Deepa, Tyhonas, John S., Urcan, Mary S., Wardlow, Marilyn, Yumibe, Nathan, Reifel-Miller, Anne · 2006 · Endocrinology
Cited by 71

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Specific retinoid X receptor (RXR) agonists, such as LG100268 (LG268), and the thiazolidinedione (TZD) PPARgamma agonists, such as rosiglitazone, produce insulin sensitization in rodent models of insulin resistance and type 2 diabetes. In sharp contrast to the TZDs that produce significant increases in body weight gain, RXR agonists reduce body weight gain and food consumption. Unfortunately, RXR agonists also suppress the thyroid hormone axis and generally produce hypertriglyceridemia. Heterodimer-selective RXR modulators have been identified that, in rodents, retain the metabolic benefits of RXR agonists with reduced side effects. These modulators bind specifically to RXR with high affinity and are RXR homodimer partial agonists. Although RXR agonists activate many heterodimer partners, these modulators selectively activate RXR:PPARalpha and RXR:PPARgamma, but not RXR:RARalpha, RXR:LXRalpha, RXR:LXRbeta, or RXR:FXRalpha. We report the in vivo characterization of one RXR modulator, LG101506 (LG1506). In Zucker fatty (fa/fa) rats, LG1506 is a potent insulin sensitizer that also enhances the insulin-sensitizing activities of rosiglitazone. Administration of LG1506 reduces both body weight gain and food consumption and blocks the TZD-induced weight gain when coadministered with rosiglitazone. LG1506 does not significantly suppress the thyroid hormone axis in rats, nor does it elevate triglycerides in Sprague Dawley rats. However, LG1506 produces a unique pattern of triglycerides elevation in Zucker rats. LG1506 elevates high-density lipoprotein cholesterol in humanized apolipoprotein A-1-transgenic mice. Therefore, selective RXR modulators are a promising approach for developing improved therapies for type 2 diabetes, although additional studies are needed to understand the strain-specific effects on triglycerides.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/en.2005-0690

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 71

Metadata

Authors
Leibowitz, M. D., Ardecky, R. J., Boehm, M. F., Broderick, C. L., Carfagna, M. A., Crombie, D. L., D’Arrigo, J., Etgen, G. J., Faul, M. M., Grese, T. A., Havel, H., Hein, N. I., Heyman, R. A., Jolley, D., Klausing, K., Liu, S., Mais, D. E., Mapes, C. M., Marschke, K. B., Michellys, P.-Y., Montrose-Rafizadeh, C., Ogilvie, K. M., Pascual, B., Rungta, D., Tyhonas, J. S., Urcan, M. S., Wardlow, M., Yumibe, N., & Reifel-Miller, A.
Venue
Endocrinology
Published
2006-02
Volume
147
Issue
2
Pages
1044-1053
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2096639035
Cited by
71
References
6
FWCI
2.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/en.2005-0690
The paper
Leibowitz, M. D., Ardecky, R. J., Boehm, M. F., Broderick, C. L., Carfagna, M. A., Crombie, D. L., D’Arrigo, J., Etgen, G. J., Faul, M. M., Grese, T. A., Havel, H., Hein, N. I., Heyman, R. A., Jolley, D., Klausing, K., Liu, S., Mais, D. E., Mapes, C. M., Marschke, K. B., . . . Reifel-Miller, A. (2006). Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes. Endocrinology. https://doi.org/10.1210/en.2005-0690

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.